At 17.2x earnings and 17.4x forward earnings, the stock is priced like a no-growth staple despite generating a 13.30% ROIC and maintaining an Altman Z-Score of 4.1, which signals strong balance sheet safety and negligible bankruptcy risk. A Market Cap of $13,551M against a Price/Sales of 3.5 and Price/Book of 3.3 suggests the market is not assigning a premium multiple to its asset base or revenue durability. The Piotroski F-Score of 6 indicates stable, not spectacular, operational health, but combined with a 2.8 current ratio and modest 29.60% Debt/Equity, the financial profile is clearly solid. This looks more like a conservatively priced defensive compounder than a distressed name, implying limited downside but also muted expectations baked into the multiple.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.